comparemela.com

Latest Breaking News On - Study clinical global impression - Page 1 : comparemela.com

BioVie to announce topline data from Phase 3 Alzheimer s Disease trial by year-end

BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in.

Joseph palumboAd cooperative studyDrug administrationBiovie incScale cognitiveStudy clinical global impressionStatistical analysis plan

Methylphenidate Safe and Effective in Reducing Apathy in Alzheimer Disease

Methylphenidate at 10 mg twice daily for reducing apathy in patients with Alzheimer disease has a sustainable effect for at least 6 months.

United statesNeuropsychiatric inventoryStudy clinical global impression

vimarsana © 2020. All Rights Reserved.